0
Clinical Investigations: ASTHMA |

Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis*

Ghassan A. Alothman, MD; Bernard Ho, BSc; Muslim M. Alsaadi, MD, ABP; Sharon L. Ho, BSc, RRT; Lisa O’Drowsky, BSc, RRT; Emily Louca, BSc, RRT; Allan L. Coates, BEng (Elect), MDCM
Author and Funding Information

*From the Division of Respiratory Medicine, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Correspondence to: Allan L. Coates, BEng, MDCM, Division of Respiratory Medicine, Hospital for Sick Children, 555 University Ave, Toronto, ON, Canada M5G IX8; e-mail: allan.coates@sickkids.ca



Chest. 2005;127(2):522-529. doi:10.1378/chest.127.2.522
Text Size: A A A
Published online

Study objective: Inhaled colistin is used for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients despite reports of chest tightness and bronchospasm. The main objective of the study was to assess whether bronchospasm occurred in pediatric CF patients with or without clinical evidence of airway hyperreactivity.

Design and methods: A prospective placebo-controlled clinical trial with crossover design was devised using challenge tests with 75 mg colistin in 4 mL saline solution and a placebo solution of the same osmolarity using a breath-enhanced nebulizer for administration. Subjects were recruited as follows: high risk (HR) for bronchospasm due to a personal history of recurrent wheezing, a family history of asthma and/or atopy, or bronchial lability, as demonstrated in pulmonary function tests; or low risk (LR) without these characteristics.

Results: The mean FEV1 (expressed as the mean [± SD] fall from baseline) of the HR group (n = 12) fell 12 ± 9% after placebo was administered, and fell 17 ± 10% after colistin was administered. For the LR group (n = 8), the mean FEV1 fell 9 ± 4% following placebo administration and 13 ± 8% following colistin administration. There was a greater number of subjects in the HR group compared to the LR group, which had a mean fall in FEV1 of ≥ 15% (p < 0.01) after inhaling colistin. The differences between placebo and colistin therapy in the LR group were not significant.

Conclusion: The results demonstrated that colistin can cause bronchospasm, particularly in those patients with coexisting CF and asthma.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543